No headlines found.
ACCESS Newswire (Tue, 8-Sep 6:00 AM ET)
ACCESS Newswire (Thu, 27-Aug 9:30 AM ET)
ACCESS Newswire (Thu, 27-Aug 8:55 AM ET)
DataMeds AI Reports Second Quarter 2026 Financials and Provides Business Update
ACCESS Newswire (Mon, 17-Aug 9:01 AM ET)
ACCESS Newswire (Fri, 14-Aug 5:25 PM ET)
DataMeds AI Provides Update on Corexa Health's Pharmacy Division
ACCESS Newswire (Wed, 12-Aug 7:40 AM ET)
ACCESS Newswire (Mon, 10-Aug 8:30 AM ET)
ACCESS Newswire (Thu, 6-Aug 8:15 AM ET)
ACCESS Newswire (Wed, 5-Aug 8:30 AM ET)
DataMeds AI's Corexa Pharmacy Launches Tollo Health's Tollovid(R) and Galactovid(TM)
ACCESS Newswire (Fri, 31-Jul 8:30 AM ET)
DataMEDS AI Inc is a healthcare technology and pharmaceutical logistics company. The group simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. Its solutions provide a single, integrated platform for pharmacies, wholesale distribution, and a fulfillment network focused on Independent Pharmacies and Specialty Lite medications.
Datameds Ai trades on the NASDAQ stock market under the symbol MEDS.
As of September 10, 2026, MEDS stock price climbed to $0.89 with 48,976 million shares trading.
MEDS has a market cap of $2.73 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that MEDS belongs to (by Net Assets): VXF, VTI.
MEDS support price is $.76 and resistance is $.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MEDS shares will trade within this expected range on the day.
